Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8831892 | 1.00 | TSHR (0.46) | TSHRMAPTRAB9ATRPM8CDC7 | |
| SCHEMBL13885706 | 0.88 | MAPT (0.46) | TSHRMAPTTRPM8HTR2BALDH1A1 | |
| SCHEMBL12130911 | 0.87 | DPP4 (0.43) | TSHRMAPTALDH1A1 | |
| SCHEMBL5622788 | 0.85 | MAPT (0.49) | TSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL14481262 | 0.84 | MAPT (0.44) | TSHRMAPTTRPM8HTR2BALDH1A1 | |
| SCHEMBL17898128 | 0.82 | RARB (0.44) | TSHRMAPTALDH1A1 | |
| SCHEMBL4415767 | 0.79 | HTR2B (0.49) | TSHRMAPTRAB9AHTR2B | |
| SCHEMBL723266 | 0.79 | HTR2B (0.49) | TSHRMAPTRAB9AHTR2B | |
| SCHEMBL1683655 | 0.79 | HTR2B (0.49) | TSHRMAPTRAB9AHTR2B | |
| SCHEMBL6829016 | 0.78 | ALOX5 (0.42) | TSHRMAPTRAB9ATRPM8CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069134-A1 | Process for producing optically active alpha-substituted cysteine or salt thereof, intermediate therefor, and process for producing the same | KANEKA CORPORATION (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1548013-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-SUBSTITUTED CYSTEINE OR SALT THEREOF, INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6894170-B2 | Process for the preparation of substituted thiazolines and their intermediates | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2005-05-17 | — | — | US | disclosed |
| US-20050101782-A1 | Process for the preparation of substituted thiazolines and their intermediates | KRICH SYLVIA (AT) | 2005-05-12 | — | — | US | disclosed |
| US-20030088105-A1 | Process for the preparation of substituted thiazolines and their intermediates | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-05-08 | — | — | US | disclosed |
| EP-1302467-A2 | Process for the preparation of substituted thiazoline derivatives and their intermediate | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088105-A1 | Process for the preparation of substituted thiazolines and their intermediates | CBR1, RCOR1, MT-CO1 | TSHR 913/4885MAPT 1838/4885RAB9A 1369/4885 |
| US-20060069134-A1 | Process for producing optically active alpha-substituted cysteine or salt thereof, intermediate therefor, and process for producing the same | CTH, SLC7A11, CBS | TSHR 3648/4885MAPT 3644/4885RAB9A 2729/4885 |
| US-20050101782-A1 | Process for the preparation of substituted thiazolines and their intermediates | CBR1, CBR3, MT-CO1 | TSHR 1045/4885MAPT 2823/4885RAB9A 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.